Literature DB >> 27417494

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.

Karin Stettler1, Martina Beltramello1, Diego A Espinosa2, Victoria Graham3, Antonino Cassotta4, Siro Bianchi1, Fabrizia Vanzetta1, Andrea Minola1, Stefano Jaconi1, Federico Mele5, Mathilde Foglierini5, Mattia Pedotti5, Luca Simonelli5, Stuart Dowall3, Barry Atkinson3, Elena Percivalle6, Cameron P Simmons7, Luca Varani5, Johannes Blum8, Fausto Baldanti6, Elisabetta Cameroni1, Roger Hewson3, Eva Harris2, Antonio Lanzavecchia4, Federica Sallusto9, Davide Corti10.   

Abstract

Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1) were largely ZIKV-specific and were used to develop a serological diagnostic tool. In contrast, antibodies against E protein domain I/II (EDI/II) were cross-reactive and, although poorly neutralizing, potently enhanced ZIKV and DENV infection in vitro and lethally enhanced DENV disease in mice. Memory T cells against NS1 or E proteins were poorly cross-reactive, even in donors preexposed to DENV. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious virus. An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27417494     DOI: 10.1126/science.aaf8505

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  359 in total

1.  Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection.

Authors:  Anzhong Li; Miaoge Xue; Zayed Attia; Jingyou Yu; Mijia Lu; Chao Shan; Xueya Liang; Thomas Z Gao; Pei-Yong Shi; Mark E Peeples; Prosper N Boyaka; Shan-Lu Liu; Jianrong Li
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Persistent Zika Virus Clinical Susceptibility despite Reduced Viral Burden in Mice with Expanded Virus-Specific CD8+ T Cells Primed by Recombinant Listeria monocytogenes.

Authors:  Ashley R Burg; John J Erickson; Lucien H Turner; Giang Pham; Jeremy M Kinder; Sing Sing Way
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

3.  Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design.

Authors:  Chunpeng Yang; Fang Zeng; Xinyu Gao; Shaojuan Zhao; Xuan Li; Sheng Liu; Na Li; Chenglin Deng; Bo Zhang; Rui Gong
Journal:  J Biol Chem       Date:  2019-05-28       Impact factor: 5.157

4.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

5.  Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion.

Authors:  Benjamin O Fulton; David Sachs; Megan C Schwarz; Peter Palese; Matthew J Evans
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Authors:  Feng Long; Michael Doyle; Estefania Fernandez; Andrew S Miller; Thomas Klose; Madhumati Sevvana; Aubrey Bryan; Edgar Davidson; Benjamin J Doranz; Richard J Kuhn; Michael S Diamond; James E Crowe; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-14       Impact factor: 11.205

Review 7.  Zika virus vaccines: immune response, current status, and future challenges.

Authors:  Justin M Richner; Michael S Diamond
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

Review 8.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

Review 9.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

Review 10.  Zika virus - reigniting the TORCH.

Authors:  Carolyn B Coyne; Helen M Lazear
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.